NCT02115165 2026-04-06
CABA-GCT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
Clinical Trials
30 trialsNCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT03114254 2022-11-18
JAVA-P
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03101046 2022-02-10
TACTIK
UNICANCER
Phase 2 Completed
NCT01913652 2021-09-14
Ph II Cabazitaxel DD Liposarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01620242 2021-03-02
ORL03
UNICANCER
Phase 2 Completed
NCT02560337 2020-10-08
CaTo-ROC
Vejle Hospital
Phase 2 Completed
NCT02512458 2020-02-10
CABA-BONE
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01956149 2018-04-18
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT01757171 2018-04-03
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01866449 2017-10-26
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
University of Ulm
Phase 2 Completed
NCT01693549 2017-08-01
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01518283 2017-07-02
Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT01528163 2017-06-14
RACATREX
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT01438307 2017-05-24
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT01541007 2015-11-02
ConCab
Karolinska University Hospital
Phase 2 Completed
NCT01852578 2015-09-28
Cabazitaxel in Relapsed and Metastatic NSCLC
Hellenic Oncology Research Group
Phase 2 Completed
NCT01600339 2015-05-12
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
Rambam Health Care Campus
Phase 2 Completed
NCT01500720 2015-04-13
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed